Company Fact Sheet - Immune Pharmaceuticals

IMMUNE
Pharmaceuticals
COMPANY PROFILE:
have broad applications across a range of disease states,
and Immune is exploring opportunities in nonalcoholic
steatohepatitis (NASH) and severe asthma as well. The
Company is developing AmiKet, a phase III ready topical
drug for the treatment of Neuropathic Pain and is seeking
a development and commercial partner. Immune is also
developing NanomAb®, antibody nanoparticle conjugates
for the targeted delivery of chemotherapeutics. Immune has
strategic partnerships with Yissum Research Development
Company of the Hebrew University of Jerusalem and STC
Immune Pharmaceuticals, Inc. (NASDAQ: IMNP),
headquartered in New York City, applies a personalized,
bio-marker based approach to treating inflammatory
diseases and cancer through the development of novel,
targeted, monoclonal antibody therapeutics. Immune’s
lead clinical candidate bertilimumab targets eotaxin-1, a
mediator of inflammation. The candidate is in Phase II trials
for ulcerative colitis (UC) and bullous pemphigoid (BP),
with initial human data expected in late 2015 for BP and
the second half of 2016 for UC. Bertilimumab may
biologics, a Cambridge-based biotech company.
2015 Milestones / Catalysts
Resume patient
enrollment process for
phase II in BP and UC
with Bertilimumab
Orphan Drug
designation for
Bertilimumab
in BP
Pre-clinical
Data availability
for Bertilimumab
in NASH
Initial Results of
Bertilimumab
Bullous Pemphigoid
(BP) phase II study
Initiation of
Bertilimumab NASH
clinical development
program
Q2 2015
Q3 2015
Q3 2015
Q4 2015
Q4 2015
Quarter
2
Quarter
3
Quarter
4
Partnering
of AMIKET
US IND filing
for Bertilimumab
in BP
Initiation of Amiket
NP development
NanomAb
Partnerships
Initiation of
Amiket PHN
phase III
Q2 2015
Q2 2015
Q3 2015
Q3/Q4 2015
Q4 2015
SENIOR MANAGEMENT TEAM:
ANALYST COVERAGE:
Dr. Daniel Teper, Chief Executive Officer
Paul Nadler, MD, Chief Medical Officer
Gad Berdugo, Chief Financial Officer
Gbola Amusa, MD—Chardan Capital Markets
Vernon T. Bemardino—MLV & Co.
Jerry Isaacson, PhD—LifeSci Advisors
Jason Napodano—Zacks Investment Research, Inc.
BOARD OF DIRECTORS:
Daniel Kazado, Chairman
Cameron Durrant, MD, Lead Independent Director
and Chair of the Compensation Committee
Elliot Maza, Chair of the Audit Committee
Rene-Pierre Azria, Chair of the Transaction Committee
Dr. Daniel Teper, Chief Executive Officer
CONTACT:
Anna Baran​
Senior Director, Corporate Affairs
IMMUNE Pharmaceuticals Inc.
430 East 29th Street, Suite 940, New York, NY 10016
Phone: 646-440-9311
anna.baran@immunepharma.com
High Levels of Eotaxin-1 Are Expressed In Patients With Inflammatory Diseases
in Multiple Organs
Liver diseases and
Gastro-Enterology
Respiratory
Severe Asthma
Non Alcoholic SteatoHepatitis (NASH)
Primary Sclerosing
Cholangitis (PSC)
Ulcerative Colitis
Crohn’s Disease
Dermatology
Bullous Pemphigoid
Eotaxin-1/ CCL11
Bullous Pemphigoid (BP) BP is a rare autoimmune blistering
cured, it can be managed. The addressable global market for
skin disease that typically affects individuals older than 65 years.
biologics in severe asthma is expected to reach $7.5 billion in sales.
Currently, there is no cure for BP. The US/EU market size is
Nonalcoholic steatohepatitis (NASH) NASH is liver inflammation
currently estimated at 60,000 patients. The addressable global
market for Bertilimumab in BP could reach $1.6 billion.
and damage caused by a buildup of fat in the liver. NASH is the
most severe form of non-alcoholic fatty liver disease (NAFLD)
IBD (Crohn’s and Colitis) Crohn’s disease and ulcerative colitis
and is regarded as a major cause of cirrhosis of the liver of
are debilitating chronic inflammatory diseases of the digestive
unknown cause. The market for NASH drugs is expected to grow
tract. The estimated market for biologics in moderate-to-severe
to over $10 billion
IBD patients is estimated to grow to $10 billion.
Companion Diagnostic Eotaxin-1/ CCL11 is a biomarker
Severe asthma Asthma is a chronic, inflammatory lung disease that
of multiple inflammatory diseases. Immune plans to develop a
narrows the airways. Severe asthma attacks may require emergency
companion diagnostic which may support patient selection
care and can be fatal. While asthma is a disease that cannot be
for personalized and targeted treatment.
Clinical Stage Portfolio With Multiple Shots on Goal Resources Prioritized For
Bertilimumab Phase II BP And UC Trials